Advanced Enzyme Q1 FY27: consolidated PAT down 4.6% YoY as margins compress

Advanced Enzyme Technologies' consolidated (primary) revenue from operations rose a modest 2.1% YoY to ₹189.79 Cr, but consolidated net profit fell 4.6% YoY to ₹38.59 Cr (EPS ₹3.31 vs ₹3.57 a year ago), and both metrics were down sharply QoQ (revenue -6.7%, PAT -14.7%) against the seasonally strong March quarter. There were no exceptional items in either this quarter or the year-ago quarter, so the reported YoY figures are also the adjusted ones — the profit decline is a genuine operating story, not a base-effect from one-offs. The drag was margins, not the topline: operating margin compressed to roughly 26.9% from 30.4% a year ago and 31.2% last quarter, and net margin slipped to 20.3% from 20.8% YoY, driven by depreciation and other-expense lines growing faster than revenue. Management's prior concall guidance (Q4 FY26, May 2026) had called for double-digit revenue growth aspiration for FY27 with margins 'largely stable' within 1-2% variability while flagging near-term cost pressure from input and logistics costs — this quarter's 2.1% revenue growth falls well short of that aspiration, and the ~350-430 bps margin compression exceeds the guided variability band, so the quarter reads as a miss against the company's own outlook. No formal street consensus estimates for this specific quarter could be located, so vsStreet is marked unknown rather than inferred. Standalone results, secondary to consolidated, showed revenue down a modest 7.3% YoY to ₹115.86 Cr and PAT down 69.8% YoY to ₹22.35 Cr — but the prior-year quarter's standalone PAT was inflated by an outsized ₹53.85 Cr other-income line (likely dividend income from subsidiaries booked in that quarter) versus just ₹2.29 Cr this year, so the standalone YoY comparison is not operationally meaningful; QoQ standalone PAT was essentially flat (+0.2%). Alongside the results, the Board approved a ₹69.7 Cr open-market share buyback (up to ₹500/share, max ~13.94 lakh shares, 1.24% of equity) and moves to make JC Biotech a wholly owned subsidiary by buying the remaining 4.28% stake for ₹7.98 Cr, plus up to ₹2 Cr further infusion into Advanced Nutrazyme — capital-allocation actions concurrent with, but not directly explaining, the margin softness. No management press release or commentary on the quarter's drivers was available in the filing beyond the standard notes. Going into Q2 FY27, the print sets up a need to show either a reacceleration toward the double-digit revenue growth management aspired to, or a stabilisation of the margin trend that has now moved outside the guided band for two consecutive quarters on a YoY basis.